Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

PROGENICS

WKN: 910678  ISIN: US7431871067  Ticker-Symbol: PGP 
Aktie:
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROGENICS Chart 1 Jahr
1-Woche-Intraday-Chart
PROGENICS 1-Woche-Intraday-Chart

Aktuelle News zur PROGENICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
25.05. -
21.05. -
11.05. -
08.05. 1
03.05. 2
25.04. 59
WASHINGTON (dpa-AFX) - Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration, or FDA, has extended the Prescription Drug...
Mehr lesen zu:
Salix, Progenics Announce FDA Extension Of RELISTOR SNDA Goal Date To July 27
25.04. -
25.04. 29
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals (NASDAQ: PGNX) today announced that the Food and Drug Administration (FDA) has extended the Prescription...
Mehr lesen zu:
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012
24.04. 42
CHICAGO, April 24, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals
12.04. -
04.04. -
02.04. 2
20.12. 68
WASHINGTON (dpa-AFX) - Shares of Salix Pharmaceuticals Ltd. (SLXP) and Progenics Pharmaceuticals Inc. (PGNX) rose on Tuesday, after Salix reported a successful late-stage trial of oral methylnaltrexone...
Mehr lesen zu:
Salix, Progenics Shares Rise On Positive Constipation Drug Study Results
20.12. 40
WASHINGTON (dpa-AFX) - Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals, Inc. (PGNX) announced the successful outcome of the Phase 3 trial to assess the efficacy and safety...
Mehr lesen zu:
Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone
20.12. 39
NDA Submission Targeted for Mid 2012 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) today announced the...
Mehr lesen zu:
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
15 Nachrichten in den letzten 6 Monaten